HK Stock Market Move | MEDBOT-B(02252) rose more than 3%. The single-arm single-hole endoscopic surgery Siasun Robot & Automation obtained approval from the National Medical Products Administration.

MEDBOT-B(02252) rose more than 3%, reaching a 3.2% increase as of the time of writing, trading at 18.06 Hong Kong dollars, with a trading volume of 84.46 million Hong Kong dollars. On the news front, Siasun Robot& Automation announced that the independently developed Tianmai single-arm single-hole endoscope surgery Siasun Robot& Automation (Tianmai single-arm) has obtained registration approval from the National Medical Products Administration (NMPA), indicating that its overall performance, innovation level, clinical effectiveness, and safety have been certified by the national regulatory authority. The approval of the Tianmai single-arm registration by the NMPA is another important milestone in the development of the group's business, which will further enhance the group's product portfolio and compatibility with the Tianmai series Siasun Robot& Automation, gradually achieving multi-arm, single-arm, remote integration, which will help enhance the competitiveness of the company's products in the domestic and international markets. Siasun Robot& Automation previously announced that the total orders for the group's core products in endoscopy, orthopedics, and vascular intervention have exceeded 100 units over the past 24 years. During this period, the global orders for Tianmai endoscopic surgery Siasun Robot& Automation reached 39 units, with commercial installations exceeding 30 units and a global cumulative commercial order of nearly 60 units. As of now, the cumulative number of successful remote surgeries for Tianmai is close to 300 cases, with a success rate of 100%. Tianmai has submitted market certification applications in more than 20 countries or regions and is expected to receive intensive approval by 2025.